In April 2012, Mr. Kobayashi was appointed President & Representative Director of Taiho Pharmaceutical Co. Since 1993, he has taken on various roles at Taiho, working in both clinical research and sales. From 2002 to 2010, Mr. Kobayashi launched Taiho Pharma USA, Inc., as President and CEO of the company. He went on from there to serve as President and CEO of Otsuka America, Inc. from June 2010 to March 2012. Masayuki Kobayashi graduated from Gakushuin University in 1989.
Timothy Whitten joined Taiho Oncology in 2013 as the Senior Vice President and CCO to build the first commercial business unit for Taiho in the West and to oversee the company’s commercial functions. In 2017, Mr. Whitten was promoted to Senior Vice President and COO, adding human resources and operations of Taiho Pharma Canada, Inc. to his responsibilities. On January 1, 2018, Mr. Whitten was promoted to President, Taiho Oncology, Inc., and given a position on the Taiho Oncology Board of Directors as he assumed leadership responsibility for corporate, commercial and clinical development-related functions at Taiho Oncology. In addition, Mr. Whitten serves as President of Taiho Pharma Canada and holds a seat on the Taiho Pharma Canada Board, as well as having operational responsibility for Taiho Pharma Europe, Ltd. As of April 1, 2018, Mr. Whitten has been named President and CEO of Taiho Oncology, reporting directly to Masayuki Kobayashi, President and Representative Director Pharmaceutical Co., Ltd., headquartered in Tokyo, Japan, following Eric Benn’s retirement as CEO, Taiho Oncology, Inc. Prior to joining Taiho Oncology, Inc., Mr. Whitten served as President and CEO of Transave/lnsmed from 2006 to 2012. During this time, he guided the company’s lead product from the preclinical stage into a global phase 3 program. In 2010, Mr. Whitten took the private company, Transave, into the public marketplace via a business combination with lnsmed. From 2001 to 2006, Mr. Whitten was employed by Pharmacyclics, where he served in various roles, including Senior Vice President, Marketing & Sales, and Business Development. Mr. Whitten spent 17 years at Bristol-Myers Squibb, where he served in various sales, marketing, and strategic planning roles, including Vice President, Marketing, for the U.S. Oncology and Immunology franchise and Vice President, Global Marketing, Oncology, Immunology, and Pulmonary Diseases. Among his accomplishments, including several product launches, he directed the successful introduction of Taxol® into the U.S. oncology market. Mr. Whitten graduated from West Virginia University with a Bachelor of Science in Pharmacy and from the University of Virginia with a Master of Business Administration.
Taiho Oncology’s Canadian leadership team brings strong leadership to the North American marketplace, while staying true to Taiho’s legacy of developing the highest quality pharmaceuticals that improve the lives of people everywhere.
Ross Glover is the General Manager of Taiho Pharma Canada, Inc. Ross is the leader of the Taiho Pharma Canada Executive Team and oversees the Commercial and Medical operations for the company in Canada. He has more than 25 years of commercial experience in the pharma industry and he has launched four business units in oncology and neurology to bring the newest and most innovative drugs to the market.
Prior to joining Taiho Pharma Canada, Inc., Ross was a member of the Canadian Leadership Team at Sanofi Genzyme and led the MS business unit to record successes for launching two new molecules. Prior to that, Ross held senior leadership positions in oncology and neurology and had built multi-functional teams to support the business and the clinical direction for breast cancer, colon cancer, lymphoma, epilepsy, Parkinson’s disease, and multiple sclerosis. Ross has extensive experience in navigating the complicated Regulatory and Market Access process and has worked to develop some unique outcomes while making drugs available for patients who are in need.
Ross has a Bachelor of Science in Biology with a specialization in Physiology from Concordia University (BSc SPEC ’88). Ross is an active community member, a certified diver, sailor and professional skier, and a married father of three boys with a busy family life.
Pieter Kooiman is the Director of Finance with Taiho Pharma Canada, Inc. Pieter is responsible for all aspects of Taiho Pharma Canada’s finance function, including financial reporting, budgeting and forecasting, cash management, finance business partnering and the effective functioning of internal controls. He has 20 years of experience in innovative pharmaceutical industry, with an additional three years in the pharmacy and pharmaceutical logistics industry.
Prior to joining Taiho Pharma Canada, Inc., Pieter held senior finance leadership roles as Director of Finance, Retail Banner and Technology Solutions for McKesson Canada, and Finance Lead Established Brands and Director of Finance, Commercial for AstraZeneca Canada. Pieter has extensive experience providing strategic financial counsel and support to many business areas including Sales and Marketing, Corporate Affairs, Market Access and Legal. He led the development of brand performance metrics, co-developed pricing strategies for launch and established products, contributed to the successful outcome of Intellectual Property cases and directly negotiated and coordinated licensing deals resourced across several international sites. Pieter started his career with the Advisory, Assurance and Tax firm Ernst Young.
Pieter holds both the Chartered Professional Accountant/Chartered Accountant and US certified Public Accountant designations, and has a Bachelor of Commerce and graduate Diploma in Public Accounting from McGill University. He has been active in his community, having coached boys’ soccer and hockey for many years and has supported such causes as Childhood Cancer Canada, Movember and Princess Margaret Road Hockey to Conquer Cancer.
Dr. Aastha Dolley is the Medical Director at Taiho Canada and has been with the company for three months. She is responsible for providing medical support to the company’s product development strategy and post marketing commitments, while supporting Medical Affairs strategy related to approved and pipeline oncology products.
Prior to joining Taiho Canada, Dr. Aastha Dolley was with AstraZeneca Canada (AZC) as Medical Advisor, Oncology. At AZC, she was responsible for the lung and thyroid cancer therapeutic areas, not only for the established brands, but also for pipeline compounds. She came to AZC from UCB Canada, where she was the Senior Medical Advisor for their neurology business unit, the MSL Manager and involved in developing a team of neurology MSLs.
Prior to joining UCB Canada, Aastha was the Associate Director, Medical Affairs at Wyeth India and was responsible for the Medical Advisors/MSLs in the Women’s Health/Hospital Antibiotic business units. She has gained more than 12 years of oncology experience while working for Novartis and Johnson & Johnson in their oncology therapeutic area.
Aastha is an MD, with specialization in Internal Medicine and Clinical Pharmacology. She was born in Mumbai, India and worked as an internist for a few years prior to joining the pharmaceutical industry in 2002.